BP1001-A in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.

Trial Details

NCT ID
NCT04196257
Phase
PHASE1
Sponsor
Bio-Path Holdings, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
Locations (sample)
  • Silver Spring, Maryland, United States|38.99067,-77.02609
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Dallas, Texas, United States|32.78306,-96.80667
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • All participants, ≥ 18 years of age, with histologic evidence of advanced or recurrent solid tumors, who are not candidates for regimens or protoco…
  • ECOG Performance Status Score of 0 or 1.
  • Participants must be willing to undergo pre-treatment biopsies. Participants who complete 1 cycle of treatment will undergo post-treatment biopsies…
  • For the dose expansion phase, participants must have recurrent or persistent epithelial ovarian, primary peritoneal, fallopian tube or endometrial …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →